Directorate Change

Silence Therapeutics plc ("Silence" or the "Company")

BOARD CHANGE

26 June 2013

Resignation of director

David Mack, non-executive director, is stepping down from the board of the Company ahead of today's annual general meeting. Based in San Francisco, he has been a director of the Company since the acquisition in 2010 of Intradigm Corporation. Alta Partners, where he is a director, disposed of its holding in Silence in November 2012. The board would like to express their thanks and appreciation to David for his work on the board of the Company, and wish him every success in his future endeavours.

For further information please contact:

Silence Therapeutics

Ali Mortazavi, chief executive/Timothy Freeborn, finance director +44 (0)333 988 0140

a.mortazavi@silence-therapeutics.com

t.freeborn@silence-therapeutics.com

N+1 Singer

Shaun Dobson/Jenny Wyllie

+44 20 7496 3000

shaun.dobson@n1singer.com

jenny.wyllie@n1singer.com